Browse Articles

Improving medication adherence is recognized as one of the most impactful and cost-effective strategies for improving the health of the general population. Here, Baryakova and colleagues assess the potential of next-generation drug delivery systems to mitigate many common impediments to adherence and discuss the impact that drug delivery systems have had across different disease types.

Move over degraders; proximity-inducing drugs that stabilize, phosphorylate and inhibit their targets are coming through.

Aled Edwards celebrates 20 years of open science at the Structural Genomics Consortium — and keeps calling for more focus on understudied proteins.

Patients and the wider public are beneficiaries of scientific research that leads to new drugs and medical technologies, but they can and should be able to contribute to these advances through participation in clinical studies, co-design of research and input into regulatory processes.

Bivalent protein degraders such as proteolysis targeting chimeras (PROTACs) are entering clinical trials, with a current focus on oral administration. O’Brien Laramy et al. propose that implementing non-oral drug delivery technologies guided by pharmacokinetic–pharmacodynamic modelling could expand the chemical design space for degraders as well as the number of druggable targets.

Hans Clevers, head of Pharma Research & Early Development at Roche, discusses the role for organoids in drug discovery and development.